Teva Pharmaceutical Industries Ltd: insider trades · United States · SEC (Form 4)

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company listed on the NYSE/NASDAQ and closely tied to the U.S. market, while remaining headquartered in Israel. The company was incorporated in Israel on February 13, 1944, with roots tracing back to a predecessor established in 1901. For investors, Teva is best understood as a hybrid healthcare group: it combines a large generics franchise with biosimilars, over-the-counter products and a focused portfolio of innovative medicines. Its broader portfolio also includes certain distribution, API and contract manufacturing activities, although management has stated that the API business is held for sale as part of the company’s strategic reshaping. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm?utm_source=openai)) Operationally, Teva runs its business across three main geographic segments: the United States, Europe and International Markets. That structure allows the company to manage its full product portfolio regionally, from generics and biosimilars to branded innovative medicines. Teva says it employs about 37,000 people and operates in 57 markets, underscoring a broad commercial and manufacturing footprint. In competitive terms, Teva remains one of the world’s leading generic-drug companies and a major player in complex generics and biosimilars, with a particularly strong strategic presence in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312525125044/d830217d424b5.htm?utm_source=openai)) Strategically, Teva has been repositioning its business around its “Pivot to Growth” roadmap. The plan emphasizes growth from innovative launches, expansion in biosimilars, a more optimized generics portfolio and margin improvement. In May 2025, the company announced its Transformation programs with a target of $700 million in net savings by 2027, highlighting a sharper focus on cost discipline and capital allocation. Its 2026 proxy statement also describes an “Accelerate Growth” phase built on new launches, a stronger pipeline and continued optimization of the generics platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312526134756/d11977ddef14a.htm?utm_source=openai)) On the product side, Teva’s key franchises include AUSTEDO, AJOVY, UZEDY, COPAXONE, BENDEKA and TREANDA, alongside a broad generics portfolio. Recent SEC filings show that U.S. revenue is still materially supported by generics, while innovative products such as AUSTEDO have become important growth drivers. Recent business developments include a biosimilar partnership with Alvotech related to an Eylea candidate and continued portfolio simplification. Overall, Teva is a large multinational pharma company in transition: still anchored by generics, but increasingly trying to build a more innovation-led earnings profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818686/000119312525076837/d576379dars.pdf?utm_source=openai))